SHAPERON First-in class anti-inflammatory NME targeting TGR5 For atopic dermatitis, ulcerative colitis, sepsis and Alzheimer’s disease SHAPERON API Increases number of immune regulatory cells resolving inflammation such as myeloid-derivedspan suppressor cells or regulatory T cells SHAPERON Novel platform for nanobody-drug conjugates for enhanced tissue distribution and lower side effects of conventional ADC 1 3